Patent Analysis


mRNA Cancer Therapeutics Patent Landscape

mRNA Cancer Therapeutics Patent Landscape Analysis 2024: By Carrier: Vesicle, Virus, Peptide, Lipid, Polymer; By Design: Self-Amplifying mRNA, Conventional Non-Amplifying mRNA; By Route of Administration: Tumoral, Parenteral, Other; By Therapy Type: Immunomodulator, mRNA Encoded Antibody, Modified Antigen Receptor, Antigen via DC Loading, Antigen via Direct Injection; Key Player Profiles

mRNA Cancer Therapeutics Market Size

The mRNA cancer therapeutics market was valued at USD 13.23 billion in 2023. It is expected to grow at a CAGR of 14.56% during the forecast period of 2024-2032 and attain a market value of USD 32.13 billion by 2032.


The market is expected to grow due to the increasing adoption of targeted therapy, and combination therapy for cancer treatment. Immunotherapies such as checkpoint inhibitors is a critical advancement in the treatment of cancer. The patent landscape of mRNA therapeutics is rapidly revolving as multiple companies have filed their patent applications to protect their inventions.


Patent Landscape Report Coverage

The mRNA Cancer Therapeutics Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this industry. The key sections captured in the report for mRNA cancer therapeutics include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within mRNA cancer therapeutics technologies.


The COVID-19 pandemic has highlighted the need for the development of more advanced vaccines. As a result, scientists are keen to develop therapeutics and diagnostics based on mRNA technologies. Hence, patent claims are crucial for the protection of the latest inventions. This has led to an increase in the number of patent applications, impacting the patent landscape significantly.


For instance, in April 2024, Moderna announced that it had been granted a patent for a cancer treatment with a lipid nanoparticle containing mRNA encoding a tethered interleukin-12 polypeptide as its administering method. This innovative approach aims to inhibit or reduce tumor growth in patients.


mRNA Cancer Therapeutics Patent Outlook

  • Innovations in delivery technologies such as lipid nanoparticles (LNPs), polymer, and immune modulation techniques are likely to be patentable as companies are trying to improve the efficacy and safety of mRNA therapies.
  • Big pharmaceutical companies, biotech firms, and research and academic institutions are actively patenting mRNA technology for cancer treatment. Moreover, emerging startups are also contributing to the patent landscape as they are focusing on developing innovative approaches in mRNA technologies.
  • The United States, and European countries are the most active applicants of mRNA-based vaccines. The top companies include Moderna and CureVac. They have filed patent applications for a wide range of vaccines, signifying their treatment efficiency.


What are mRNA therapeutics?

Messenger RNA or mRNA is a type of single-stranded ribonucleic acid that is transcribed from a strand of DNA. It carries the coding information for protein synthesis. The development of mRNA-based therapeutics mainly includes mRNA entrapment, mRNA design, synthesis, pharmacodynamics, pharmacokinetics, and safety evaluation in vivo and in vitro.


The successful result of COVID-19 mRNA vaccines has accelerated confidence to utilize this RNA-based technology. This has led to an increase in investment activities across the pharmaceutical industry. As more therapies move through clinical trials, patent filings are expected to increase.


For instance, with the success of the mRNA COVID- 19 vaccines, an investigational vaccine mRNA-4157-P201 received breakthrough therapy designation in 2023. Jointly developed by Moderna in combination with checkpoint inhibitor pembrolizumab (Merck), it is intended to treat high-risk melanoma.


mRNA Cancer Therapeutics Industry Growth Drivers

Surge in Research and Development Activity is Expected to Boost Patent Industry Growth

The mRNA-based therapy is expected to be useful in multiple treatments including cancer. These drugs offer the advantages of low side effects and higher efficiency.


In April 2024, a clinical trial study reported successful results using mRNA technology for pancreatic cancer treatment. The data shows that the investigational mRNA vaccine can trigger T cells (the cells that mobilize anti-tumor immune responses).


Another promising trial by The University of Cincinnati Cancer Center for a pancreatic cancer vaccine introduces a novel approach to cancer treatment. This approach uses mRNA technology which instructs the immune system to target pancreatic cancer cells by recognizing their unique genetic markers.


The development of innovative clinical approaches to treat cancer has led to patent filing by multiple companies. In August 2022, Regen Biopharma filed a p atent on an mRNA cancer immunotherapy vaccine. The patent was filed with USPTO. Hence, the increase in patent filing is impacting the patent landscape positively.


Advancements in Delivery Platform is Expected to Propel mRNA Cancer Therapeutics Patent Industry Growth

The continuous developments in mRNA synthesis and delivery technologies expand the patent landscape. The innovative developments in delivery platforms like lipid nanoparticles (LNPs), enhance the efficacy and safety of mRNA therapies.


LNP has several advantages over other delivery technologies like its ability to carry multiple mRNAs in one formulation, is minimally immunogenic, and ease of scaling up. The development of these innovative technologies impacting the patent landscape as companies are protecting their intellectual property rights.


mRNA Cancer Therapeutics Patent Segmentation

The report will cover the following sections in detail:


Breakup by Carrier

  • Vesicle
  • Virus
  • Peptide
  • Lipid
  • Polymer


Breakup by Design

  • Self-Amplifying mRNA
  • Conventional Non-Amplifying mRNA


Breakup by Route of Administration

  • Tumoral
  • Parenteral
  • Other


Breakup by Therapy Type

  • Immunomodulator
  • mRNA Encoded Antibody
  • Modified Antigen Receptor
  • Antigen via DC Loading
  • Antigen via Direct Injection


mRNA Cancer Therapeutics Patent Segmentation Analysis

The breakup based on design includes self-amplifying mRNA and conventional non-amplifying mRNA. Self-amplifying RNA (saRNA) vaccines utilize a self-replicating RNA platform to produce immune responses in the body. The RNA vaccines aim to stimulate the immune system to defend against specific pathogens. However, RNA vaccines use genetic material, specifically, messenger RNA, instead of using inactivated viruses, and instruct cells to produce a protein.


The detailed technological data will be provided for all specified segments classified in this report.


mRNA Cancer Therapeutics Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for mRNA cancer therapeutics patents, having around 101,000+ patents. The presence of major pharmaceutical companies, well-established healthcare infrastructure, advanced research and development activities and strong legal framework contributes to the patent landscape significantly.


Patent Profile of Key Companies

Among the players with mRNA cancer therapeutics patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:


Pfizer, Inc.

Pfizer, Inc. founded in 1849 and headquartered in the United States is a global pharmaceutical company engaged in the development of medicines and vaccines in multiple therapeutic areas including cancer, cardiovascular diseases, and neurology among others. Pfizer is developing innovations in mRNA-based technologies for oncology with vaccine development programs for flu and shingles, along with respiratory combination vaccines.


Novartis AG

Novartis AG, founded in 1996 is headquartered in Switzerland. It is a global pharmaceutical company, engaged in the development of therapies in multiple areas including oncology, respiratory diseases, neurological disorders, and diabetes among others. The company is developing innovative RNA-targeting therapies which have the potential to target and reduce tumors. Novartis has filed numerous patents to protect its IPs within mRNA technologies.


Other companies include Genentech Inc., Immatics Biotechnologies Gmbh, and Modernatx Inc., among others.


Reasons to Purchase this Report

The mRNA cancer therapeutics patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -


  • Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and also makes it understandable which companies have important patents in this field of mRNA cancer therapeutics.
  • Innovation Insights: The patent analysis reveals new innovations and technologies in mRNA cancer therapeutics industry.
  • Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.
  • Risk Assessment: In technology-intensive fields such as mRNA cancer therapeutics, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.


Scope of the Report Details
Analysis by Carrier
  • Vesicle
  • Virus
  • Peptide
  • Lipid
  • Polymer
Analysis by Design
  • Self-Amplifying mRNA
  • Conventional Non-Amplifying mRNA 
Analysis by Route of Administration
  • Tumoral
  • Parenteral
  • Other 
Analysis by Therapy Type
  • Immunomodulator
  • mRNA Encoded Antibody
  • Modified Antigen Receptor
  • Antigen via DC Loading
  • Antigen via Direct Injection
Key Players Mentioned
  • Pfizer, Inc.
  • Novartis AG
  • Genentech Inc.
  • Immatics Biotechnologies GmbH
  • Modernatx Inc.
  • Others
Geographies Covered
  • North America
  • Europe
  • Asia Pacific
  • Others


Key Questions Answered in the mRNA Cancer Therapeutics Patent Landscape Report

  • Who are the key players in the mRNA cancer therapeutics patent landscape?
  • How is the patent portfolio distributed geographically?
  • What are the emerging trends in mRNA cancer therapeutics patents?
  • How has the patent landscape evolved over time?
  • What are the strategic insights for market players and investors?
  • What is the technological focus of patents in the mRNA cancer therapeutics industry?
  • How do patent strategies impact competitive advantage?
  • What are the implications of patent filings in mRNA cancer therapeutics?
  • What are the challenges and opportunities in the mRNA cancer therapeutics patent landscape?
  • What are the regulatory and legal considerations?
  • What technological innovations have recently emerged in mRNA cancer therapeutics?


Related Reports

Global Cancer Immunotherapy Market

Global Cancer Vaccines Market

Global Immunotherapy Drugs Market

Global Monoclonal Antibodies Market


*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Introduction
2    Executive Summary
3    Global mRNA Vaccine and Therapeutic Market Overview 

    3.1    Global mRNA Vaccine and Therapeutic Market Historical Value (2017-2023) 
    3.2    Global mRNA Vaccine and Therapeutic Market Forecast Value (2024-2032)
4    Global mRNA Vaccine and Therapeutic Market Segmentation 
    4.1    Global mRNA Vaccine and Therapeutic Market Share by Type
        4.1.1    Market Overview
        4.1.2    Self-Amplifying mRNA Vaccines
        4.1.3    Non-Amplifying mRNA Vaccines
    4.2    Global mRNA Vaccine and Therapeutic Market Share by Route of Administration
        4.2.1    Market Overview
        4.2.2    Intravenous
        4.2.3    Intramuscular
        4.2.4    Intranasal
        4.2.5    Others
    4.3    Global mRNA Vaccine and Therapeutic Market Share by Therapeutic Area
        4.3.1    Market Overview
        4.3.2    Infectious Diseases 
        4.3.3    Oncological Disorders
        4.3.4    Other Disorders
5    Global Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    Porter’s Five Forces Analysis
    5.3    PESTEL Analysis 
    5.4    Industry Events, Initiatives, and Trends  
    5.5    Value Chain Analysis
6    Global mRNA Cancer Therapeutics Patent Landscape Analysis
    6.1    Patent Distribution by Publication Year
    6.2    Patent Distribution by Application Year
    6.3    Patent Distribution by Priority Year
    6.4     Analysis by Type of Patent
        6.4.1    Granted Patents 
        6.4.2    Patent Application
        6.4.3    Amended Application
        6.4.4    Search Report
    6.5    Analysis by Legal Status
        6.5.1    Active 
        6.5.2    Pending 
        6.5.3    Expired/Discontinued 
    6.6    Analysis by Patent Jurisdiction
    6.7    Analysis by Patent Age
    6.8    Analysis by Cooperative Patent Classification (CPC) Codes
    6.9    Average Time to Publish a Patent
        6.9.1    By Entities
        6.9.2    By Jurisdiction
        6.9.3    By Technology
    6.10    Analysis by Type of Entity (Academic and Non-Academic)
    6.11    Analysis by Top Applicants
    6.12    Analysis by Top Inventors
7    Global mRNA Cancer Therapeutics Patent Analysis by Technology
    7.1    Total Patents by Top Technologies 
    7.2    Time Evolution of Patents by Technology
    7.3    Emerging Technologies
    7.4    Patent Segmentation, By Carrier
        7.4.1    Time Evolution by Number of Patents
        7.4.2    Time Evolution by Number of Patent Families
        7.4.3    Analysis by Type of Entity (Academic vs Non-Academic)
        7.4.4    Analysis by Top Applicants
        7.4.5    Analysis by Top Inventors
    7.5    Patent Segmentation, By Route of Administration
    7.6    Patent Segmentation, By Delivery Route
*Complete technology list will be provided in the report.
8    EMR Patent Valuation Analysis
    8.1    Assessment Methodology
    8.2    High Value Patents
    8.3    Medium Value Patents
    8.4    Low Value Patents
9    Global mRNA Cancer Therapeutics – Top 10 Players Patent Analysis 
    9.1    Top 10 Entities by Number of Patents
    9.2    Analysis by Publication Year
    9.3    Analysis by Application Year
    9.4    Analysis by Priority Year
    9.5    Analysis by Type of Patent
    9.6    Analysis by Jurisdiction
    9.7    Analysis by Cooperative Patent Classification (CPC) Codes
    9.8    Analysis by Source of Innovation 
    9.9    Analysis by Forward and Backward Citations
    9.10    Analysis by Legal Status
    9.11    Analysis by Patent Age
    9.12    Analysis by Key Inventors
    9.13    Entity Dynamics
        9.13.1    Analysis by Type of Player (Academic vs Non-Academic)
        9.13.2    Analysis by Collaboration 
        9.13.3    Analysis by Technology
        9.13.4    Newcomers 
      Start-up Companies
      Established Companies
10    Patent Profile of Key Players
    10.1    Pfizer, Inc.
        10.1.1    Product Portfolio
        10.1.2    Patent Portfolio by Patent Families
        10.1.3    Time Evolution of Patents
        10.1.4    Geographical Patent Coverage 
        10.1.5    Patent Analysis by Technology
        10.1.6    Patent News and Developments
        10.1.7    Financial Analysis
        10.1.8    SWOT Analysis
    10.2    Modernatx Inc 
    10.3    Novartis AG
    10.4    Genentech Inc. 
    10.5    Immatics Biotechnologies GmbH
11    Future Trends
12    Global mRNA Vaccine and Therapeutic Market Landscape (Additional Insight)* 

    12.1    Global mRNA Vaccine and Therapeutic: Developers Landscape
        12.1.1    Analysis by Year of Establishment
        12.1.2    Analysis by Company Size
        12.1.3    Analysis by Region
    12.2    Global mRNA Vaccine and Therapeutic: Product Landscape 
        12.2.1    Analysis by Product Type
        12.2.2    Analysis by Technology
        12.2.3    Analysis by Application


*Additional insights are not provided in the standard report.

Purchase Full Report

Mini Report

$ 2639     $2399
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 4399     $3999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 5829     $5299
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 6929     $6299
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.